Aldeyra Therapeutics (ALDX) director receives long-dated stock option awards

Rhea-AI Filing Summary

Aldeyra Therapeutics, Inc. director Darlene M. Deptula‑Hicks received two stock option grants to acquire common stock at an exercise price of $1.72 per share.

One option for 9,756 shares vests in equal annual installments over three years after June 9, 2026. A second option for 84,557 shares becomes exercisable for all shares on the one‑year anniversary of the grant date if she continues serving on the Audit Committee. Both options expire on June 8, 2036.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider DEPTULA-HICKS DARLENE M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	84,557	$0.00	--
Grant/Award	Stock Option (Right to Buy)	9,756	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 84,557 shares (Direct, null)

Footnotes (1)

1. The stock option is exercisable in equal annual installments over three years of continuous service to the Issuer after June 9, 2026. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.

Key Figures

Option grant size: 9,756 options Second option grant size: 84,557 options Exercise price: $1.72 per share +3 more

6 metrics

Option grant size 9,756 options Stock Option (Right to Buy) grant to director on June 9, 2026

Second option grant size 84,557 options Stock Option (Right to Buy) grant to director on June 9, 2026

Exercise price $1.72 per share Conversion/exercise price for both option grants

Option expiration June 8, 2036 Expiration date for both option grants

Post-grant holdings (small grant) 9,756 options Total derivative securities following transaction for 9,756-share grant

Post-grant holdings (large grant) 84,557 options Total derivative securities following transaction for 84,557-share grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, Audit Committee, +1 more

5 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with underlying common stock and exercise price"

exercise price financial

"conversion or exercise price of $1.72 per share for both grants"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"exercisable in equal annual installments over three years of continuous service"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Audit Committee financial

"service as a member of the Audit Committee of the Board of Directors"

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

grant/award acquisition financial

"transaction action described as grant/award acquisition for the options"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DEPTULA-HICKS DARLENE M

(Last) (First) (Middle)

C/O ALDEYRA THERAPEUTICS, INC.

131 HARTWELL AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aldeyra Therapeutics, Inc. [ ALDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.72	06/09/2026		A		84,557		(1)	06/08/2036	Common Stock	84,557	$0	84,557	D
Stock Option (Right to Buy)	$1.72	06/09/2026		A		9,756		(2)	06/08/2036	Common Stock	9,756	$0	9,756	D

Explanation of Responses:

1. The stock option is exercisable in equal annual installments over three years of continuous service to the Issuer after June 9, 2026.

2. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.

	/s/ Darlene Deptula-Hicks	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Aldeyra Therapeutics (ALDX) report for Darlene Deptula-Hicks?

Aldeyra reported two stock option grants to director Darlene M. Deptula-Hicks. She received options covering 9,756 and 84,557 shares of common stock, both with a $1.72 exercise price and expiring June 8, 2036, as equity-based compensation awards.

What are the terms of the 9,756-share stock option granted by Aldeyra Therapeutics (ALDX)?

The 9,756-share stock option has a $1.72 exercise price and expires June 8, 2036. It becomes exercisable in equal annual installments over three years of continuous service to Aldeyra after June 9, 2026, aligning vesting with ongoing board responsibilities.

How does the 84,557-share Aldeyra Therapeutics (ALDX) option vest for Darlene Deptula-Hicks?

The 84,557-share option vests 100% on the one-year anniversary of the June 9, 2026 grant date. Vesting requires that Darlene M. Deptula-Hicks continues serving as a member of Aldeyra’s Audit Committee through that vesting date, linking compensation to committee service.

What is the exercise price and expiration date of the new Aldeyra Therapeutics (ALDX) options?

Both option grants to Darlene M. Deptula-Hicks carry a $1.72 per share exercise price. Each option expires on June 8, 2036, providing a long-dated opportunity to acquire Aldeyra common stock if vesting conditions and service requirements are satisfied over time.

Are the new Aldeyra Therapeutics (ALDX) option grants open-market purchases or compensation awards?

The transactions are compensation-related stock option awards, not open-market purchases. They are coded as grants or awards, with no purchase price paid at grant, and vesting is tied to Darlene M. Deptula-Hicks’s continued service on Aldeyra’s board and Audit Committee.